Phio Pharmaceuticals

Phio Pharmaceuticals Announces Addition of Clinical Trial Sites at Banner MD Anderson Cancer Center, The George Washington University, and Integrity Research

Retrieved on: 
Wednesday, March 13, 2024
Research, Gene silencing, George Washington, Phio Pharmaceuticals, Skin cancer, George Washington University, Merkel-cell carcinoma, Patient, Associate, Clinical trial, Safety, Banner, Melanoma, PD-1

Banner MD Anderson Cancer Center in Gilbert, Arizona

Key Points: 
  • Banner MD Anderson Cancer Center in Gilbert, Arizona
    Integrity Research Clinical Associates in Delray Beach, Florida
    These sites join Centricity Research in Dublin, Ohio, which enrolled the study’s first patient in November.
  • The principal investigator at the George Washington University trial is Vishal Patel, M.D.
  • at the Banner MD Anderson Cancer Center trial site.
  • More information about this clinical trial is available at clinicaltrials.gov (identifier: NCT06014086 ).

Phio Pharmaceuticals Announces Patent Granted by USPTO, Strengthening the Company’s Intellectual Property Position in Treating Aging Skin and Skin Disorders

Retrieved on: 
Wednesday, March 6, 2024
Lentigo, Pigment, Metabolism, Melasma, Elasticity, UVR, Ageing, Patent, Phio Pharmaceuticals, Skin, Hyperpigmentation, Gene silencing, TYR, Downregulation and upregulation, Iodosobenzene, MMP1, Vaccine

The compounds treat age-related skin disorders including photo-aging and dermal hyperpigmentation, targeting the down-regulation of the Matrix metalloproteinase-1 (MMP1) and Tyrosinase (TYR) proteins.

Key Points: 
  • The compounds treat age-related skin disorders including photo-aging and dermal hyperpigmentation, targeting the down-regulation of the Matrix metalloproteinase-1 (MMP1) and Tyrosinase (TYR) proteins.
  • Ultraviolet radiation (UVR) exposure is a known contributor to skin cancer and aging, inducing the hyperactivity of MMP1 which increases collagen breakdown and reduces collagen synthesis.
  • “We have a robust patent portfolio for Phio’s INTASYL siRNA technology,” said Robert Bitterman, CEO of Phio Pharmaceuticals.
  • “The addition of this recent patent grant for treatment of photodamaged skin is complementary to our current initiative in treating skin cancer.”

Phio CEO to Speak at Wainwright Conference in New York in September

Retrieved on: 
Wednesday, September 6, 2023
Lotte New York Palace Hotel, Phio Pharmaceuticals, FDA, EST, Conference, Pharmaceutical industry

Mr. Bitterman will discuss the recent FDA IND approvals for Phio’s lead product, PH-762; PH-762 is currently cleared for two clinical trials.

Key Points: 
  • Mr. Bitterman will discuss the recent FDA IND approvals for Phio’s lead product, PH-762; PH-762 is currently cleared for two clinical trials.
  • Mr. Bitterman will also review the Company’s evolution from discovery to development, highlighting the new, industry-experienced leadership team he has put in place to lead this transformation.
  • The presentation will become available online at 7:00 am EST on Monday, September 11th.
  • The Conference will be taking place September 11th—13th at the Lotte New York Palace Hotel in New York City.

Phio Pharmaceuticals Announces Dosing of First Patient in Collaborative Clinical Trial with AgonOx, Inc. and Providence Cancer Institute

Retrieved on: 
Monday, August 21, 2023
TIL, CSO, Clinical trial, Cancer, Immunotherapy, Translation, Organization, Phio Pharmaceuticals, CD8, DP, Patient, Melanoma, Principal, PD-1, FDA, Laboratory, Safety, Vaccine, Pharmaceutical industry

The clinical trial is one of two studies cleared by the FDA which will utilize Phio’s lead product candidate, PH-762.

Key Points: 
  • The clinical trial is one of two studies cleared by the FDA which will utilize Phio’s lead product candidate, PH-762.
  • The trial is being conducted at Providence Cancer Institute in Portland, Oregon, by Principal Investigator Brendan Curti, M.D., medical oncologist and Robert W. Franz Endowed Chair for Clinical Research at the Earle A. Chiles Research Institute, a division of Providence.
  • “Our institute has been at the leading edge of immunotherapy clinical research including checkpoint immunotherapy, novel co-stimulatory agents and cancer vaccines,” said Dr. Curti.
  • “This is an important collaborative milestone between these organizations in the advancement of treatments for solid tumors,” said Robert Bitterman, President and CEO of Phio Pharmaceuticals.

Phio Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Thursday, May 11, 2023
ACT, Abstract, AACR, Gene, Phio Pharmaceuticals, Cancer, American Association for Cancer Research, NK, Research, CD8, Patent, Patient, DP, Melanoma, Cell, TIGIT, American Society of Gene and Cell Therapy, Society, Safety, Vaccine, Pharmaceutical industry, Life insurance, Iodosobenzene

MARLBOROUGH, Mass., May 11, 2023 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective in killing tumor cells, today reported its financial results for the quarter ended March 31, 2023 and provided a business update.

Key Points: 
  • MARLBOROUGH, Mass., May 11, 2023 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective in killing tumor cells, today reported its financial results for the quarter ended March 31, 2023 and provided a business update.
  • At March 31, 2023, the Company had cash of $9.0 million as compared with $11.8 million at December 31, 2022.
  • Research and development expenses increased 35% to approximately $2.1 million for the quarter ended March 31, 2023 compared with approximately $1.6 million for the quarter ended March 31, 2022.
  • General and administrative expenses increased 39% to approximately $1.5 million for the quarter ended March 31, 2023 compared with approximately $1.1 million for the quarter ended March 31, 2022.

Global TIL Therapies Market Report 2023 to 2035: Key Players Include Bristol-Myers Squibb, CAR-T (Shanghai) Cell Biotechnology, Cellectis and Incyte - ResearchAndMarkets.com

Retrieved on: 
Wednesday, February 1, 2023
Biotechnology, Pharmaceutical, Health, TILS, Investment, Cellectis, Head, Melanoma, Lymphocyte, Nature, NK, Macrophage, Patient, Clinical trial, Moving target indication, Neoplasm, USD, Mayo Collaborative Services v. Prometheus Laboratories, Inc., Growth, TIL, Bristol Myers Squibb, Antigen, Phio Pharmaceuticals, Cancer, Sales, Medical imaging, Pharmaceutical industry

The "Global TIL Therapies Market : Distribution by Target Indication, Key Players and Key Geographical Regions: Industry Trends and Global Forecasts, 2023-2035" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global TIL Therapies Market : Distribution by Target Indication, Key Players and Key Geographical Regions: Industry Trends and Global Forecasts, 2023-2035" report has been added to ResearchAndMarkets.com's offering.
  • The report features an extensive study of the current market landscape and future opportunity for the players focused on the development of TIL therapies.
  • This report features an extensive study of the current market landscape and future opportunity for the players focused on the development of TIL therapies.
  • Overall, we are led to believe that the global TIL therapies market is poised to witness significant growth in the foreseen future.

Phio Showcases Innovations in Dermatology Cancers at 2023 Dermatology Summit in San Francisco

Retrieved on: 
Friday, January 6, 2023
Hyatt Regency Houston, Conference, Phio Pharmaceuticals, Iodosobenzene, Dermatology, RNA interference, Hyatt, Therapy, Medical imaging

The Dermatology Summit is taking place at the Hyatt Regency, alongside the annual JPMorgan Healthcare Conference.

Key Points: 
  • The Dermatology Summit is taking place at the Hyatt Regency, alongside the annual JPMorgan Healthcare Conference.
  • Mr. Bitterman will discuss innovations in dermatological cancers, highlighting Phio's proprietary INASTYL™ platform.
  • Mr. Bitterman was recently appointed to his leadership role at Phio.
  • He previously led Cutanea and Dermik in the development and commercialization of small molecule dermatological products.

Phio Pharmaceuticals Announces Appointment of Robert Bitterman as Executive Chairman

Retrieved on: 
Thursday, September 29, 2022
Therapy, RNA interference, Director, Company, Phio Pharmaceuticals, Industry, Patient, Audit committee, BS, Lehigh University, Board of directors, Lead, Board, Tumor microenvironment, Immune system, Management

(Nasdaq: PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprietary self-delivering RNAi (INTASYL) therapeutic platform, today announced the appointment of Robert Bitterman as interim Executive Chairman of the Board of Directors (the "Board").

Key Points: 
  • (Nasdaq: PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprietary self-delivering RNAi (INTASYL) therapeutic platform, today announced the appointment of Robert Bitterman as interim Executive Chairman of the Board of Directors (the "Board").
  • As Executive Chairman, Mr. Bitterman will assume the duties of principal executive officer and principal financial officer and will lead all aspects of the Company's operations.
  • The Company is also pleased to announce the appointment of Robert Ferrara as Lead Independent Director of the Board.
  • Phio Pharmaceuticals Corp.(Nasdaq: PHIO) is a clinical stage biotechnology company developing the next generation of immuno-oncology therapeutics based on its self-delivering RNAi (INTASYL) therapeutic platform.

Phio Pharmaceuticals Announces Acceptance of Six Abstracts at The 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Retrieved on: 
Monday, September 12, 2022
Risk, Therapy, RNA interference, Immunotherapy, TIGIT, Company, Phio Pharmaceuticals, Review, Private Securities Litigation Reform Act, Neoplasm, BRD4, Patient, Forward-looking statement, 2021 Essex County Council election, Technology, CTGF, Annual report, Nasdaq, Coronavirus, SITC, Tumor microenvironment, SEC, PD-1, Immune system, Pharmacotherapy, Society, TIL, Pharmaceutical industry, Research

"We are pleased to announce the acceptance of six posters for presentation at the annual SITC meeting.

Key Points: 
  • "We are pleased to announce the acceptance of six posters for presentation at the annual SITC meeting.
  • The team is excited to share the results of these programs during these upcoming posters at SITC."
  • Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a clinical stage biotechnology company developing the next generation of immuno-oncology therapeutics based on its self-delivering RNAi (INTASYL) therapeutic platform.
  • This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

Phio Pharmaceuticals Announces the Appointment of Patricia A. Bradford to its Board of Directors

Retrieved on: 
Monday, May 2, 2022
Board, Board of directors, Forward-looking statement, Private Securities Litigation Reform Act, Immune system, Tax, Senior, Nasdaq, Company, Time, Tumor microenvironment, Patient, Chief human resources officer, Coronavirus, Review, Risk, Audit, Unisys, Deloitte, Cancer, Annual report, RNA interference, Therapy, Accreditation, CPA, SEC, Technology, Phio Pharmaceuticals, Iodosobenzene, Pharmaceutical industry, Management

"We are delighted to welcome Patricia to the Phio Board.

Key Points: 
  • "We are delighted to welcome Patricia to the Phio Board.
  • "We believe that Patricia will be an effective steward of the Company and counselor to the management team."
  • Ms. Bradford stated, "I am excited to join the Phio Board at such an important period in the Company's history, when the first INTASYL therapeutic compounds are entering the clinic this year.
  • Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a clinical stage biotechnology company developing the next generation of immuno-oncology therapeutics based on its self-delivering RNAi (INTASYL) therapeutic platform.